FI870981A - Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. - Google Patents

Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. Download PDF

Info

Publication number
FI870981A
FI870981A FI870981A FI870981A FI870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A FI 870981 A FI870981 A FI 870981A
Authority
FI
Finland
Prior art keywords
ricintoxin
producerats
mikrobisk
kedja
rekombinant
Prior art date
Application number
FI870981A
Other languages
English (en)
Other versions
FI870981A0 (fi
Inventor
Robert Ferris
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of FI870981A0 publication Critical patent/FI870981A0/fi
Publication of FI870981A publication Critical patent/FI870981A/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809Fused cells, e.g. hybridoma

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI870981A 1986-03-06 1987-03-05 Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik. FI870981A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83684886A 1986-03-06 1986-03-06
US06/905,283 US4689401A (en) 1986-03-06 1986-09-09 Method of recovering microbially produced recombinant ricin toxin a chain

Publications (2)

Publication Number Publication Date
FI870981A0 FI870981A0 (fi) 1987-03-05
FI870981A true FI870981A (fi) 1987-09-07

Family

ID=27125896

Family Applications (1)

Application Number Title Priority Date Filing Date
FI870981A FI870981A (fi) 1986-03-06 1987-03-05 Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik.

Country Status (7)

Country Link
US (1) US4689401A (fi)
EP (1) EP0237297A1 (fi)
AU (1) AU596153B2 (fi)
CA (1) CA1308680C (fi)
DK (1) DK118887A (fi)
FI (1) FI870981A (fi)
NO (1) NO870668L (fi)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956453A (en) * 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4985541A (en) * 1987-04-10 1991-01-15 Zymogenetics, Inc. Novel cytotoxic protein
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
WO1989004839A1 (en) * 1987-11-24 1989-06-01 Genetics Institute, Inc. Improved ricin molecules and ricin toxin conjugates
ATE195142T1 (de) * 1991-02-26 2000-08-15 Zeneca Ltd Fermentationsverfahren zur herstellung von peptiden durch einen wirt
USH1985H1 (en) 1992-01-09 2001-08-07 The United States Of America As Represented By The Secretary Of The Navy Method for detecting biological toxins
US5453271A (en) * 1993-06-28 1995-09-26 The United States Of America As Represented By The Secretary Of The Army Vaccine against ricin toxin
US5437986A (en) * 1994-06-22 1995-08-01 Schering Corporation Extraction of heterologous insoluble proteins from bacteria
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
JP4813364B2 (ja) 2003-11-25 2011-11-09 アメリカ合衆国 突然変異型抗cd22抗体および免疫複合体
US8580927B2 (en) 2008-01-31 2013-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered antibody constant domain molecules
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP3135692B8 (en) 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
PL3434346T3 (pl) 2010-07-30 2021-04-06 Medimmune, Llc Oczyszczone aktywne polipeptydy lub immunokoniugaty
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP2764025B1 (en) 2011-10-04 2017-11-29 IGEM Therapeutics Limited Ige-antibodies against hmw-maa
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
SG11201407972RA (en) 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
US9416190B2 (en) 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014100443A2 (en) 2012-12-20 2014-06-26 Medimmune, Llc Methods of producing immunoconjugates
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN106999578B (zh) 2014-07-31 2022-03-04 美国政府(由卫生和人类服务部的部长所代表) 针对epha4的人类单克隆抗体和其用途
CA2989347A1 (en) 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108779162B (zh) 2015-10-09 2021-12-07 美天施生物科技有限公司 嵌合抗原受体和使用方法
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
AU2017321894A1 (en) 2016-09-02 2019-03-14 Lentigen Technology, Inc. Compositions and methods for treating cancer with duoCARs
WO2018119279A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
ES2936803T3 (es) 2017-01-09 2023-03-22 Lentigen Tech Inc Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
CA3057838A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
CA3059472A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
EP3661964A1 (en) 2017-07-31 2020-06-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
EP4279584A3 (en) 2017-10-16 2024-03-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
CA3086612A1 (en) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
AU2019301675A1 (en) 2018-07-12 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
AU2019350865A1 (en) 2018-09-26 2021-04-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
JP2022513682A (ja) 2018-11-30 2022-02-09 レンティジェン・テクノロジー・インコーポレイテッド 抗cd38免疫療法によりがんを処置するための組成物および方法
US20220064324A1 (en) 2019-01-08 2022-03-03 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting mesothelin for treating solid tumors
CN113784987A (zh) 2019-01-22 2021-12-10 美国政府(由卫生和人类服务部的部长所代表) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
EP3934668A1 (en) 2019-03-06 2022-01-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
CN118345101A (zh) 2019-05-30 2024-07-16 莱蒂恩技术公司 用于用抗bcma免疫治疗来治疗癌症的组合物和方法
WO2021003297A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
CN114729041A (zh) 2019-10-22 2022-07-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
CN116829581A (zh) 2020-06-22 2023-09-29 莱蒂恩技术公司 用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3171093A1 (en) 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
CN117500831A (zh) 2021-06-09 2024-02-02 美国政府(由卫生和人类服务部的部长所代表) 用于治疗实体瘤的靶向pd-l1的跨物种单结构域抗体
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
US20240075142A1 (en) 2022-08-26 2024-03-07 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
GR79124B (fi) * 1982-12-22 1984-10-02 Genentech Inc
DE3584486D1 (de) * 1984-02-08 1991-11-28 Cetus Corp Toxinkonjugate.
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1286843C (en) * 1985-10-30 1991-07-23 Leo S. Lin Purification method for proteins
EP0866128A3 (en) * 1986-03-07 1998-12-16 Chiron Corporation Recombinant ricin toxin

Also Published As

Publication number Publication date
NO870668D0 (no) 1987-02-19
DK118887D0 (da) 1987-03-06
AU6973887A (en) 1987-09-10
CA1308680C (en) 1992-10-13
DK118887A (da) 1987-09-07
AU596153B2 (en) 1990-04-26
US4689401A (en) 1987-08-25
NO870668L (no) 1987-09-07
FI870981A0 (fi) 1987-03-05
EP0237297A1 (en) 1987-09-16

Similar Documents

Publication Publication Date Title
FI870981A0 (fi) Foerfarande foer aotervinning av ricintoxin a-kedja som producerats med hjaelp av mikrobisk rekombinant-dna-teknik.
FI873897A (fi) Maenniskans erytropoietin som framstaellts medelst rekombinations-dna-teknik.
FI86241B (fi) Foerfarande foer oeverfoering av bildsignaler med hjaelp av transformationskodning.
FI853309L (fi) Foerfarande foer behandling av taender med speciella ljuspolymeriserade blandningar som innehaoller en acylfosfinoxid omfattande katalyt.
FI871872A (fi) Logik foer minskning av hastigheten foer vindturbin med reglerbar stigning.
FI873054A0 (fi) Hydroformylering som utnyttjar litet flyktiga fosfinligander loesliga i organiska aemnen.
FI884924A (fi) Humanimmuglobulin som producerats med hybrid-dna-teknik.
FI861396A0 (fi) Braedparkett som isolerar stegljudet.
FI864649A0 (fi) Short-dwell-bestrykningsanordning foer bestrykning av en materialbana med bestrykningsmassa.
FI874375A0 (fi) Flerskedesfoeraongare med en foeraongande kondensator som vaetskefoeraongningsskede.
FI874465A (fi) Uppvaermningsanordning som anvaender mikrovaogsenergi.
FI870043A0 (fi) Foerfarande foer laddning av uppaotgaoende borrhaol med flytbara explosiva aemnen.
FI864835A (fi) Kaerllock som foerhindrar inaotdragning.
FI865312A0 (fi) Anvaendning av esterfoerening som temporaer mikrobicid.
FI864526A0 (fi) Foerfarande foer tillvaratagande av vaerme i samband med en gasturbinprocess.
FI871174A (fi) Foerfarande foer bestaemning av haptener med hjaelp av immunoanalysteknik.
FI872249A0 (fi) Foerfarande foer framstaellning av foereningar som inhiberar dopamin- -hydroxylas.
FI873320A (fi) Telekommunikationscentralutrustning med flerpartsledningar som anvaender isdn-teknik.
FI870724A0 (fi) Kraftanlaeggning med renare av centrifugaltyp foer foerbraenningsgaser.
FI873994A (fi) Foerfarande foer daempning av nedsmutsning som foerorsakats av olefinfoereningar innehaollande kolvaetekompositioner.
FI861833A0 (fi) Anordning foer maetning av kraften som paoverkar en lyftkrok.
FI923164A0 (fi) Foereningar anvaendbara som mellan- produkter.
FI865175A0 (fi) Specialmatta som glidyta.
FI861519A0 (fi) Lakutrustning som lossas hydrauliskt.
FI865072A0 (fi) Kopplingsanordning foer hopkoppling av tvao med varandra gaongjaernsfoerbunda foensterbaogar.

Legal Events

Date Code Title Description
FD Application lapsed
BB Publication of examined application
CD Patent refused following opposition
FD Application lapsed

Owner name: CETUS ONCOLOGY CORPORATION